Some small biotech companies could keep certain drugs out of Medicare price talks. To qualify, they would need few qualifying drugs and high research spending. The rule would start with the 2029 negotiation year.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Small Biotech Innovation Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Latest action on H.R. 3731: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who this affects: This bill mainly affects small biotech drug makers that have only a few qualifying drugs and spend heavily on research. It also affects Medicare, because Medicare may lose the chance to negotiate prices for some drugs made by those companies. People on Medicare could be affected too, but the bill alone does not show whether their costs would rise, fall, or stay the same.
Why this matters: This matters because Medicare price talks can lower what the program pays for some drugs. This bill would remove certain small biotech drugs from that process. Supporters may see that as help for companies that rely on a few drugs to fund research. Critics may see it as a loss of possible savings for Medicare and some patients. The real effect would depend on how many companies qualify and which drugs receive the exception.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Keep acting on Modern Action
Compare the broader issue and related bills without leaving Modern Action.
